Enzalutamide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Enzalutamide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
376
Registered trials
604
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Enzalutamide can convert its Small molecule drug profile and AR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Enzalutamide (query alias: enzalutamide) |
|---|---|
| Modality / target | Small molecule drug; AR; AR antagonists |
| Highest global status | Approved |
| Originator | Medivation LLC (California) |
| Active developers | Medivation LLC (California), Pfizer Inc., Astellas Pharma, Inc. |
The MCP disease footprint includes Prostatic Cancer, Castration-sensitive prostate cancer, HRR Gene-mutated Castration-Resistant Prostate Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07620574 | Phase 3 | Not yet recruiting | 5000 | Number of Participants With Treatment Emergent Adverse Events (TEAEs) |
| ChiCTR2600125798 | Phase 3 | Not yet recruiting | 14 | Disease progression |
| NCT07592910 | Phase 2 | Not yet recruiting | 60 | Radiographic progression free survival (rPFS) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Pharmacovigilance signals of androgen receptor pathway inhibitors in non-geriatric men with prostate cancer: A FAERS disproportionality analysis.
Not Applicable; n=1594913; evaluation: Positive. Reported fields: Asthenia = 4.79 ROR ; Asthenia = 1.69 ROR ; Asthenia = 2.11 ROR
Can TGF-β inhibition (galunisertib) enhance response to enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)?: Results from a randomized phase II trial.
Phase 2; n=61; evaluation: Negative. Reported fields: mrPFS = 7.3 month ; mrPFS = 5.6 month
Final results of Alliance A031902: A phase III trial of enzalutamide plus rucaparib as first-line therapy in metastatic castration-resistant prostate cancer (CASPAR).
Phase 3; n=61; evaluation: Negative. Reported fields: -; AE(discontinued) = 3.0 Pts
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Enzalutamide addresses Prostatic Cancer, Castration-sensitive prostate cancer, HRR Gene-mutated Castration-Resistant Prostate Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-04-22 | Astellas Pharma will assess the combination of Zenith Epigenetics' ZEN-3694 and enzalutamide for the treatment of mCRPC. | Approved | Financial terms not disclosed |
| 2020-01-27 | ORIC Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial of ORIC-101 in Combination with XTANDI® for the Treatment of Prostate Cancer in Collaboration with Astellas | Approved | Financial terms not disclosed |
| 2018-11-06 | Nektar and Pfizer collaborate to assess the effectiveness of NKTR-214 in combination with avelumab, talazoparib, or enzalutamide for the treatment of mCRPC and SCCHN. | Phase 1/2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Inherited variants in SRD5a genes and response to hormonal therapy in prostate cancer”. The milestone feed surfaced a patent-application signal described as “Acyclic glutarimide compounds, compositions comprising same, and methods of use thereof”. The milestone feed surfaced a patent-application signal described as “Use of combination of piperidine alkene compounds in preparation of drug for treating cancer”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
